Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Improved Assay Determines d-Xylose in Urine and Serum

By LabMedica International staff writers
Posted on 03 Dec 2014
A simple method for the evaluation of intestinal lactase activity in vivo has been developed and optimized in humans with potential advantages over current tests for the noninvasive diagnosis of lactase deficiency or hypolactasia.

The phloroglucinol assay is the current method for d-xylose determination in urine, plasma, or serum; however, its sensitivity is limited when low amounts of D-xylose are to be measured, such as in the noninvasive evaluation of intestinal lactase with 4-galactosylxylose (gaxilose).

Clinical chemists at the Universidad Autónoma de Madrid (Spain) obtained 25 human urine and venous blood samples from healthy subjects who attended a local hospital. More...
D-xylose and gaxilose determination in urine and serum after oral gavage of gaxilose was performed in six hypolactasic subjects with lactase activity in small intestine biopsy of less than 10 U/g protein enrolled in a multicenter, open label, nonrandomized trial, designed to address the diagnostic performance of the gaxilose test.

D-xylose determination was carried out using a modification of the phloroglucinol method and the absorbance in the colorimetric assay of D-xylose was read using a double beam spectrophotometer (Hitachi, Tokyo, Japan) set at 554 nm. A method for gaxilose determination by gas chromatography (GC) was also optimized.

The linearity of the improved D-xylose assay ranged from 0.125 to 5.0 mg/L as compared to 5 to 200 mg/L by the original method. Accuracy at the lower limit of quantification (LOQ), 0.125 mg/L, was 0.97%/2.49% in spiked urine or serum. For other quality controls (QC), it was less than 1.27%. Intra- and inter-assay precision at LOQ were 6.02% and 6.45% for urine, and 8.86% and 10.00%, respectively, for serum and for other QC; precision was less than 2.15%. Linearity of gaxilose determination by GC was 3.90 to 195.17 mg/L for urine and 9.75 to 95.17 mg/L for serum with acceptable sensitivity and reproducibility. The method proved adequate for the D-xylose determination in healthy and hypolactasic subjects after oral administration of gaxilose.

The authors concluded that the modified method provides high sensitivity and robustness for D-xylose quantification in urine and serum samples for routine clinical use especially in the noninvasive diagnosis of intestinal lactase deficiency with the gaxilose test. The study was published in the November 2014 issue of the Journal of Clinical Laboratory Analysis.

Related Links:

Universidad Autónoma de Madrid
Hitachi



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Online QC Software
Acusera 24•7
Electrolyte Analyzer
CBS-4000 (CBS-400)
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Pathology

view channel
Image: Overview of the uncertainty-aware lensfree computational pathology platform for automated HER2 assessment. A compact lensfree holographic imaging system captures diffraction patterns from immunohistochemically stained breast tissue samples, which are computationally reconstructed and analyzed using deep neural networks with Bayesian uncertainty quantification. (Photo courtesy of Ozcan Lab, UCLA)

Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer

Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.